Compugen (NASDAQ:CGEN) Upgraded by ValuEngine to Hold

ValuEngine upgraded shares of Compugen (NASDAQ:CGEN) from a sell rating to a hold rating in a research note released on Tuesday, ValuEngine reports.

A number of other research analysts have also recently commented on CGEN. Zacks Investment Research upgraded Compugen from a hold rating to a buy rating and set a $5.00 price objective on the stock in a research note on Thursday, October 31st. BidaskClub upgraded Compugen from a buy rating to a strong-buy rating in a research note on Sunday, November 3rd.

Compugen stock traded up $0.11 during mid-day trading on Tuesday, hitting $5.40. 220,900 shares of the company were exchanged, compared to its average volume of 177,471. The business’s 50 day simple moving average is $4.40 and its two-hundred day simple moving average is $3.77. The company has a market capitalization of $307.76 million, a P/E ratio of -13.17 and a beta of 2.67. Compugen has a 12-month low of $2.00 and a 12-month high of $6.22. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.38 and a quick ratio of 5.38.

Large investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN lifted its stake in shares of Compugen by 424.5% in the second quarter. Wells Fargo & Company MN now owns 7,526 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 6,091 shares in the last quarter. LPL Financial LLC acquired a new position in shares of Compugen in the second quarter worth about $43,000. D. E. Shaw & Co. Inc. acquired a new position in shares of Compugen in the second quarter worth about $45,000. Janney Montgomery Scott LLC acquired a new position in shares of Compugen in the third quarter worth about $68,000. Finally, Royal Bank of Canada lifted its stake in shares of Compugen by 115.4% in the second quarter. Royal Bank of Canada now owns 57,500 shares of the biotechnology company’s stock worth $221,000 after acquiring an additional 30,800 shares in the last quarter. Institutional investors and hedge funds own 41.98% of the company’s stock.

Compugen Company Profile

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

Featured Article: What economic reports are most valuable to investors?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.